Table 4.

Association of Epigenetic Age Acceleration With Multimorbidity Count and Multimorbidity Score Among All Women Eligible to Survive to Age 90 (N = 1 951)

	Multimorbidity Count		Multimorbidity Score
	RR (95% CI)*	p	RR (95% CI)*	p
AgeAccelHorvath	0.99 (0.96–1.02)	.651	1.01 (0.98–1.04)	.448
AgeAccelHannum	0.97 (0.94–1.01)	.105	0.98 (0.95–1.02)	.360
AgeAccelPheno	1.04 (1.00–1.07)	.040	1.07 (1.04–1.10)	<.001*
AgeAccelGrim	1.00 (0.97–1.04)	.917	0.98 (0.95–1.01)	.252

Notes: All models were adjusted for the following baseline covariates: blood cell composition (CD8T, CD4T, NK, Bcell, Mono, Gran), age, race/ethnicity, education, walking frequency, BMI, alcohol consumption, pack-years smoking, broken hip, emphysema, arthritis, depression, urinary incontinency, and visual/auditory sensory impairment; and RAND physical functioning score. There were 1 022 women who survived to age 90 and 929 women who died before age 90. All models included an offset for age to account for differing lengths of follow-up. RR = relative risk; CI = confidence interval; SD = standard deviation; BMI = body mass index.

*Results are presented for one standard deviation increase in DNAmAge measure: AgeAccelHorvath (SD = 5.1 years), AgeAccelHannum (SD = 5.3 years), AgeAccelPheno (SD = 7.0 years), and AgeAccelGrim (SD = 3.9 years).

*p < .05.